Profile
Thomas L.
Gutshall is the founder of CEPHEID, which was founded in 1996.
He served as Chairman from 2002 to 2013.
Currently, he holds director positions at Profusa, Inc., Pacific Medical Research Foundation, Silver Bullet Therapeutics, Inc., and is an advisor at 1Flourish Capital LLC.
Previously, he served as a Director at CV Therapeutics, Inc. from 1994 to 2009, and as a Director at Metrika, Inc. and Satoris, Inc. He also served as Executive Vice President at Syntex Corp.
from 1989 to 1994.
Mr. Gutshall received his undergraduate degree from the University of Delaware in 1960.
Thomas L. Gutshall active positions
| Companies | Position | Start |
|---|---|---|
Pacific Medical Research Foundation | Director/Board Member | - |
Profusa, Inc. (California)
Profusa, Inc. (California) Electronic Equipment/InstrumentsElectronic Technology Manufactures tissue integrated biosensors for continuous monitoring of body chemistries | Director/Board Member | 01/01/2012 |
Silver Bullet Therapeutics, Inc.
Silver Bullet Therapeutics, Inc. BiotechnologyHealth Technology Develops antimicrobial coating based on proprietary silver ionization technology for medical devices | Director/Board Member | - |
1Flourish Capital LLC
1Flourish Capital LLC Investment ManagersFinance 1Flourish Capital invests in companies located in the United States. The firm targets companies operating in the field of the deep technology such as physical AI, defense technology and dual-use innovation sector. It provides financing for pre-seed, seed and early-stage capital requirements. | Consultant / Advisor | - |
Former positions of Thomas L. Gutshall
| Companies | Position | End |
|---|---|---|
Satoris, Inc.
Satoris, Inc. Miscellaneous Commercial ServicesCommercial Services Develops tests for neurological diseases | Director/Board Member | 01/01/2011 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule drugs | Director/Board Member | 17/04/2009 |
Syntex Corp.
Syntex Corp. Pharmaceuticals: MajorHealth Technology Pharmaceutical concern | Corporate Officer/Principal | 01/12/1994 |
Metrika, Inc.
Metrika, Inc. BiotechnologyHealth Technology Manufactures and markets diabetes monitoring products | Director/Board Member | - |
| CEPHEID | Chief Executive Officer | 22/04/2002 |
Training of Thomas L. Gutshall
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Syntex Corp.
Syntex Corp. Pharmaceuticals: MajorHealth Technology Pharmaceutical concern | Health Technology |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule drugs | Health Technology |
CEPHEID
CEPHEID Medical SpecialtiesHealth Technology Develops, manufactures and markets molecular diagnostic systems | Health Technology |
Metrika, Inc.
Metrika, Inc. BiotechnologyHealth Technology Manufactures and markets diabetes monitoring products | Health Technology |
Satoris, Inc.
Satoris, Inc. Miscellaneous Commercial ServicesCommercial Services Develops tests for neurological diseases | Commercial Services |
Profusa, Inc. (California)
Profusa, Inc. (California) Electronic Equipment/InstrumentsElectronic Technology Manufactures tissue integrated biosensors for continuous monitoring of body chemistries | Electronic Technology |
University of Delaware
University of Delaware Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pacific Medical Research Foundation | |
Silver Bullet Therapeutics, Inc.
Silver Bullet Therapeutics, Inc. BiotechnologyHealth Technology Develops antimicrobial coating based on proprietary silver ionization technology for medical devices | Health Technology |
1Flourish Capital LLC
1Flourish Capital LLC Investment ManagersFinance 1Flourish Capital invests in companies located in the United States. The firm targets companies operating in the field of the deep technology such as physical AI, defense technology and dual-use innovation sector. It provides financing for pre-seed, seed and early-stage capital requirements. | Finance |
- Stock Market
- Insiders
- Thomas L. Gutshall
















